復星醫藥(02196.HK)子公司新藥納入突破性治療藥物程序

阿斯達克財經

2025/05/12

復星醫藥(02196.HK) 公布，控股子公司復星醫藥產業的FCN-15片用於治療兒童朗格漢斯組織細胞增生症已被納入突破性治療藥物程序。該新藥為集團自主研發的創新型小分子化學藥物，擬主要用於治療晚期實體瘤、1型神經纖維瘤病、樹突狀細胞和組織細胞腫瘤、低級別腦膠質瘤等。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-05-12 16:25。)AASTOCKS新聞

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2534827753"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534827753\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534827753?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","is_english":false,"pubTime":"2025-05-12 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534827753","market":"sh","top_or_hot":-1,"title":"復星醫藥(02196.HK)子公司新藥納入突破性治療藥物程序","media":"阿斯達克財經","content":"<div>\n<p>復星醫藥(02196.HK) 公布，控股子公司復星醫藥產業的FCN-15片用於治療兒童朗格漢斯組織細胞增生症已被納入突破性治療藥物程序。該新藥為集團自主研發的創新型小分子化學藥物，擬主要用於治療晚期實體瘤、1型神經纖維瘤病、樹突狀細胞和組織細胞腫瘤、低級別腦膠質瘤等。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-05-12 16:25。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1439322/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>復星醫藥(02196.HK)子公司新藥納入突破性治療藥物程序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n復星醫藥(02196.HK)子公司新藥納入突破性治療藥物程序\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-05-12 22:26</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>復星醫藥(02196.HK) 公布，控股子公司復星醫藥產業的FCN-15片用於治療兒童朗格漢斯組織細胞增生症已被納入突破性治療藥物程序。該新藥為集團自主研發的創新型小分子化學藥物，擬主要用於治療晚期實體瘤、1型神經纖維瘤病、樹突狀細胞和組織細胞腫瘤、低級別腦膠質瘤等。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-05-12 16:25。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1439322/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1439322/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"國家隊","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1439322/latest-news/AAFN","article_id":"2534827753","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1439322/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2534827753","pubTimestamp":1747059960,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"復星醫藥(02196.HK) 公布，控股子公司復星醫藥產業的FCN-15片用於治療兒童朗格漢斯組織細胞增生症已被納入突破性治療藥物程序。該新藥為集團自主研發的創新型小分子化學藥物，擬主要用於治療晚期實體瘤、1型神經纖維瘤病、樹突狀細胞和組織細胞腫瘤、低級別腦膠質瘤等。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-05-12 16:25。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0028":"国家队","BK1593":"医美概念股","BK0239":"医药制造","BK0183":"MSCI概念","BK1191":"制药","BK0096":"民营医院","BK0188":"融资融券","BK1515":"抗疫概念","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","02196":"复星医药","BK0060":"抗癌","BK0187":"一线龙头"},"translate_title":"Fosun Pharma (02196. HK) subsidiary's new drug included in the breakthrough therapeutic drug program","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"復星醫藥(02196.HK) 公布，控股子公司復星醫藥產業的FCN-15片用於治療兒童朗格漢斯組織細胞增生症已被納入突破性治療藥物程序。該新藥為集團自主研發的創新型小分子化學藥物，擬主要用於治療晚期實體瘤、1型神經纖維瘤病、樹突狀細胞和組織細胞腫瘤、低級別腦膠質瘤等。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-05-12 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}